Subscribe To
PCRX / After Plunging -17.19% in 4 Weeks, Here's Why the Trend Might Reverse for Pacira (PCRX)
PCRX News
By Zacks Investment Research
November 2, 2023
Pacira (PCRX) Q3 Earnings and Revenues Miss, '23 View Updated
Pacira (PCRX) announces weaker-than-expected third-quarter 2023 results. The company streamlines its 2023 guidance for net Exparel sales. more_horizontal
By Zacks Investment Research
August 2, 2023
Pacira (PCRX) Q2 Earnings and Sales Miss, '23 View Updated
Pacira (PCRX) announces weaker-than-expected second-quarter 2023 results. The company updates its 2023 financial guidance. more_horizontal
By Zacks Investment Research
May 15, 2023
Here's Why You Should Add Pacira (PCRX) Stock to Your Portfolio
Pacira (PCRX) is witnessing strong growth on the back of its lead product, Exparel. Potential label expansion is set to boost sales in future quarters more_horizontal
By GlobeNewsWire
May 9, 2023
Pacira BioSciences to Participate in Fireside Chat at the 2023 RBC Capital Markets Global Healthcare Conference
TAMPA, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fires more_horizontal
By Zacks Investment Research
May 3, 2023
Pacira (PCRX) Q1 Earnings Miss Estimates, Revenues Beat
Pacira (PCRX) misses on Q1 earnings but beats on revenues, even though volume growth of Exparel is offset by lower selling prices. more_horizontal
By Zacks Investment Research
March 30, 2023
Why Is Pacira (PCRX) Down 6% Since Last Earnings Report?
Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? more_horizontal
By Zacks Investment Research
March 30, 2023
Pacira's (PCRX) sNDA for Exparel Accepted for FDA Review
The FDA accepts Pacira's (PCRX) sNDA filing, which seeks to expand the label of its pain drug Exparel to include both sciatic and femoral nerve blocks more_horizontal
By Zacks Investment Research
March 1, 2023
Pacira's (PCRX) Q4 Earnings Match Estimates, Revenues Fall
Pacira BioSciences (PCRX) reports mixed fourth-quarter financial results, where earnings match estimates, but revenues miss the mark. more_horizontal